SRL Diagnostics

Companion Diagnostics Technologies and Global Markets Report 2023-2024 and 2028 Featuring Major Players - F. Hoffmann-La Roche, Agilent Technologies, and QIAGEN - ResearchAndMarkets.com

Retrieved on: 
星期五, 五月 3, 2024
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, Agilent Technologies, LDT, Market, Exosome, QIAGEN, Immunohistochemistry, Polymerase chain reaction, DSM-IV codes, Intelligence, SRL Diagnostics, ChromeOS, Patent, ESG, CDX, Infection, Cardiovascular disease

The current report provides detailed coverage of the companion diagnostics market.

Key Points: 
  • The current report provides detailed coverage of the companion diagnostics market.
  • This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market.
  • The report details the companion diagnostics market share based on product and service, type of test, technology, and application.
  • Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN

Neuron Launches Network APIs to Enable Application-Driven QoE On Demand for the Maritime Industry

Retrieved on: 
星期二, 四月 9, 2024
Satellite, Other Health, Technology, Managed Care, Travel, Other Transport, Artificial Intelligence, Maritime, Transport, Telecommunications, Software, Cruise, Networks, Health, Mobile, Wireless, Communication, LTE, Wi-Fi, Sunday Night Football, Partnership, Stethoscope, AI, IPTV, Video on demand, Data-rate units, SRL Diagnostics, API, Safety, Machine learning, QOS, Mobile phone

Neuron , a QoE management platform for things that move, announced today that it’s making its network APIs available to maritime solution providers and app developers to enable application-driven quality of experience (QoE) on demand.

Key Points: 
  • Neuron , a QoE management platform for things that move, announced today that it’s making its network APIs available to maritime solution providers and app developers to enable application-driven quality of experience (QoE) on demand.
  • Neuron Network APIs Enable Multi-Provider, AI-Powered Connectivity Orchestration
    With Neuron’s network APIs, maritime solution providers and app developers can connect their apps directly to Neuron’s AI-powered network management solution, Neuron Grid, to programmatically request QoE on demand.
  • “Because Neuron enables multi-provider access with AI-powered network management, we are uniquely positioned to facilitate application-driven QoE on demand for the maritime industry.
  • Neuron is committed to working with additional partners to explore new ways to use its network APIs for a diverse range of use cases.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Retrieved on: 
星期四, 三月 28, 2024
Novartis, Acute lymphoblastic leukemia, Head, LG, Translational research, Urology, Oncology, Drug discovery, Executive, LG Chem, Lung, Anschutz Medical Campus, Committee, SRL Diagnostics, University, Laboratory, Doctor of Philosophy, RWTH Aachen University, Senior, Radiopharmaceutical, European Medicines Agency, ARUP Laboratories, Therapy, Drug development, Pharmacology, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Key Points: 
  • BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
  • “We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company.
  • Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”).
  • The Scientific Advisory Committee is comprised of several leading cancer experts, including:
    Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology
    University of Colorado Cancer Center, Aurora

Companion Diagnostic Markets Transforming the Diagnostics Industry: In-Depth Analysis and Future Forecast (2023-2027) - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Research, Companion diagnostic, Organization, Application, Consultant, Hospital, SRL Diagnostics, Laboratory, Diagnosis, Future, FDA, Medical device

The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.
  • The diagnostics industry is undergoing a significant transformation with the rapid advancement of Companion Diagnostics, especially within oncology, a sector witnessing the adoption of immune-oncology practices.
  • Research on Personalized Companion Diagnostics indicates a trend toward customization in patient care, significantly impacting the future of diagnostics.
  • The future of diagnostics heralds a period of innovative, tailored solutions that elevate patient care to new heights.

Naveris Announces New Data at EUROGIN International Multidisciplinary HPV Congress 2024

Retrieved on: 
星期四, 三月 14, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ASCC, DART, Head, Disease, Associate, Patient, Oropharyngeal cancer, DNA, Anal cancer, University, Management, Cancer, MD, Pembrolizumab, HPV, SRL Diagnostics, OPC, Medicare, Recurrence, Radiation therapy, Huntsman Cancer Institute, Pharmaceutical industry

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, announced new data at EUROGIN International Multidisciplinary HPV Congress 2024 , taking place in Stockholm on March 13-16.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications, leading to recent positive Medicare and commercial insurance coverage policies.
  • The study involved 150 patients, with NavDx tested pre-treatment and every three months post-treatment and patients followed for five years.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
星期二, 二月 27, 2024
Rubius, Odyssey, Senior, Inborn errors of metabolism, Investment, Drug development, Growth, Sale, IPO, University, Intuitive Surgical, Neurodegenerative disease, Analog Devices, National academy, J. P. Morgan, MIT, Genetic distance, American Philosophical Society, Business development, Journal, Therapy, Imatinib, SRL Diagnostics, MidOcean Partners, Distinction, Laboratory, Cornell University, Drug discovery, Weill Cornell Medicine, Provost, Panasonic Executive Partner, Abbott Laboratories, Flagship, Novartis, Medtronic, MACP, Harvard Medical School, Nilotinib, American Academy, Yale School of Medicine, JPMorgan Chase, AI, MD, Flagship Pioneering, Harvard University, MassMutual, Executive, Cancer, Management

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment

Retrieved on: 
星期一, 二月 12, 2024
Division, Sepsis, Infection, Blood, Physician, Investigator, SRL Diagnostics, BSI, Fungal infection, Bloodstream infections, Standard of care, Patient, Journal, MBBS, Tufts Medical Center, Medical imaging

The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.

Key Points: 
  • The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.
  • “In this study, the Investigators demonstrated that RaPID/BSI is not prone to false positive results, which is common with assays that rely on sequencing or standard molecular diagnostic techniques.
  • Importantly, they also demonstrated that the assay can detect ongoing infections missed by follow-up cultures.
  • RaPID/BSI correctly identified 58% more ongoing infections in patients with concurrent antimicrobial therapy than follow-up blood cultures.

Cars Commerce Addresses Automotive Retailers' Top Three Pain Points to Help Them Unleash Growth in 2024

Retrieved on: 
星期二, 一月 30, 2024
Cars.com, OEM, SRL Diagnostics, Growth, Experience, Comparison, Acquisition, NADA, Original equipment manufacturer, OBD, Pain, News, Online shopping

CHICAGO, Jan. 30, 2024 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS) (d/b/a " Cars Commerce Inc. "), an audience-driven technology company empowering automotive, today shared the top three dealer pain points in 2024 and how the company plans to help its customers solve these challenges to unleash growth.

Key Points: 
  • CHICAGO, Jan. 30, 2024 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS) (d/b/a " Cars Commerce Inc. "), an audience-driven technology company empowering automotive, today shared the top three dealer pain points in 2024 and how the company plans to help its customers solve these challenges to unleash growth.
  • This news comes ahead of the 2024 NADA Show in Las Vegas Feb. 2-4, where dealers and partners can experience the Cars Commerce platform and its connected solutions live in booth #3421W.
  • We built the Cars Commerce platform to solve the connected-commerce conundrum in automotive.
  • Our platform unites the tiers and connects the shopper experience all while reducing complexity for retailers so they can sell more cars more profitably."

FordDirect Selects AccuTrade as its Preferred Vehicle Acquisition and Trade and Appraisal Solution For Its 3000+ U.S. Ford Dealers and Lincoln Retailers to Turn More Cars for More Profit

Retrieved on: 
星期三, 一月 24, 2024
Cars.com, Instant Cash, Learning, SRL Diagnostics, Consumer, Growth, The Shop, Ford, Shop, Acquisition, OBD, Vins, Online shopping

Half of the retailers leveraging the AccuTrade solution in the service drive in 2023 at least doubled their volume of service drive appraisals from January to December².

Key Points: 
  • Half of the retailers leveraging the AccuTrade solution in the service drive in 2023 at least doubled their volume of service drive appraisals from January to December².
  • "FordDirect's mission as a trusted partner and resource to our retailers is to work with the best vendors in the market to support the needs of all Ford Dealers and Lincoln Retailers.
  • "AccuTrade allows dealers to turn vehicle acquisition into a true profit center, ensuring they secure a healthy margin at the point of acquisition with a guaranteed offer backed by Cars Commerce."
  • Ford Dealers and Lincoln Retailers that are interested in learning more about AccuTrade, can visit the Cars Commerce booth (#3421W) at the 2024 NADA Show in Las Vegas Feb. 2-4 or visit www.carscommerce.inc .

Commercial Vehicle ADAS Market to grow by USD 2.52 billion from 2023 to 2028, Aptiv Plc, Autoliv Inc., Brandmotion LLC and more among key companies - Technavio

Retrieved on: 
星期五, 十二月 15, 2023
Longevity, Electronics, Electronic stability control, Advanced driver-assistance system, Continental AG, Fleet management, Growth, Driver monitoring system, ADAS, Geography, Safety, GPS, LDW, DMS, USD, ZF Friedrichshafen, Communication, TSR, Challenge, Gentex, Autoliv, Ultrasonic transducer, Intel, ACC, Build automation, Artificial intelligence, Robert Bosch GmbH, SRL Diagnostics, IVI, Virtual camera system, BSD, Commercial vehicle, ESC, EBS, Collision avoidance system, Aptiv, ITS, Emergency, Traffic-sign recognition, Telematics, Intelligent transportation system, Global Positioning System, Music, Instrumentation, Road, Automotive industry

NEW YORK, Dec. 15, 2023 /PRNewswire/ -- The commercial vehicle adas market is estimated to grow by USD 2.52 billion from 2023 to 2028, growing at a CAGR of 12.39%.

Key Points: 
  • NEW YORK, Dec. 15, 2023 /PRNewswire/ -- The commercial vehicle adas market is estimated to grow by USD 2.52 billion from 2023 to 2028, growing at a CAGR of 12.39%.
  • The commercial vehicle adas market is fragmented owing to the presence of many global and regional companies.
  • Autoliv Inc. - The company offers commercial vehicle ADAS such as driver airbags, side curtain airbags, seatbelts and pyrotechnical safety switches.
  • The commercial vehicle propeller shaft market size is estimated to grow at a CAGR of 4.64% between 2022 and 2027.